Update on the EMERALD Study from Praxis скачать в хорошем качестве

Update on the EMERALD Study from Praxis

Join us for a presentation February 10 on the EMERALD Study, evaluating the drug candidate Relutrigine. Praxis will discuss the study design and how families with GRI Disorders (GRIN, GRIA, GRIK, and GRID) are eligible to participate. Who: Individuals with any GRI Disorder, aged 2–65. Requirement: At least 4 countable seizures per month. Location: Recruiting NOW in the US. Note: This is a decentralized study, so patients across the US can participate! Future sites are also planned for Australia, Brazil, Germany, and Italy. Bonus: All participants, including those in the placebo group, will have access to Relutrigine after the initial 16-week period.